Results 71 to 80 of about 2,398,808 (296)
, 2021 Supplementary Table from Targeting a Radiosensitizing Antibody–Drug Conjugate to a Radiation-Inducible ...
Abhay K. Singh (15033101) +5 more
core +1 more source
The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
Blood and Lymphatic Cancer: Targets and Therapy, 2019 Catherine Lai,1 Adrese Michael Kandahari,1 Chaitra Ujjani2 1Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC, USA; 2Seattle Cancer Care Alliance, Fred Hutchinson CRC, University of Washington, Seattle, WA ...
Lai C, Kandahari AM, Ujjani C
doaj
Molecular Oncology, EarlyView.Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim +3 more
wiley +1 more source
Antibody Drug Conjugates for Cancer Therapy
Majallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Bābul, 2017 BACKGROUND AND OBJECTIVE: In recent decades, the use of antibody drugs conjugates (ADCs) generated promise for the treatment of cancer. In this type of treatment, a monoclonal antibody against a cancer specific antigen is used, and a cytotoxic drug is ...
S M Gheibi hayat, AH Sahebkar
doaj
Molecular Oncology, EarlyView.The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington +10 more
wiley +1 more source
Molecular Oncology, EarlyView.Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq +8 more
wiley +1 more source
Conditions for safe and effective ADEPT treatment [PDF]
, 2010 Antibody directed enzyme prodrug therapy (ADEPT) is a drug delivery system developed for the treatment of cancer. ADEPT uses a systemically administered antibody, tethered to an enzyme, to localize enzyme in tumour deposits.
Wilkins, D.K.
core
AJICAP-M: Traceless Affinity Peptide Mediated Conjugation Technology for Site-Specific Antibody-Drug Conjugate Synthesis [PDF]
A traceless site-selective conjugation method, “AJICAP-M,” was developed for native antibodies at specific sites using Fc-affinity peptides, focusing on Lys248 or Lys288. It produces antibody-drug conjugates (ADCs) with consistent drug-to-antibody ratios,
Yuichi, Nakahara +13 more
core +2 more sources
Molecular Oncology, EarlyView.Detecting circulating tumor cells (CTCs) in blood before surgery may help predict outcomes in patients with head and neck squamous cell carcinoma (HNSCC). Here, we show when combined with tumor size and lymph node involvement from routine imaging, CTC status identifies high‐risk patients with poorer survival—offering a simple, minimally invasive tool ...
Susanne Flach +9 more
wiley +1 more source
Antibody-Assisted Delivery of a Peptide–Drug Conjugate for Targeted Cancer Therapy
, 2018 A number of cancer-targeting peptide-drug conjugates (PDCs) have been explored as alternatives to antibody-drug conjugates (ADCs) for targeted cancer therapy.
Dobeen Hwang +17 more
core +1 more source